Pozuelo De Alarcon

• A first-in-human study to investigate the safety and tolerability of a new antibody-guided drug delivery treatment for patients with therapy … Recruiting
  2024-511074-80-01 7 2024-09-06 Platinum-resistant high-grade ovarian cancer (PROC) or relapsed/refrac
• First-in-Human Study of OKI-219 Alone and in Combination with Other Therapies in Patients with Solid Tumors / Breast Cancer Recruiting
  2023-508435-31-00 1 2024-08-09 Advanced Solid Tumors, Advanced Breast Cancer
• A Phase 1, Open-Label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preli … Recruiting
  2023-506199-28-00 1 2024-08-05 Dose escalation: Advanced Solid Tumors Dose Expansion: Squamous non-sm
• Dose Escalation and Dose Expansion Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Patients with Advanced … Recruiting
  2023-508178-27-00 9 2024-07-10 Participants with Advanced KRASG12C-Mutated Solid Tumors
• Dose-finding for dobutamine during transitional circulation in the very preterm infant Recruiting
  2023-504915-34-00 9 2024-06-20 Neonates with haemodynamic insufficiency
• A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants … Recruiting
  2022-501697-19-01 5 2024-06-18 Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leuke
• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting
  2023-503631-18-01 5 2024-05-20 Nervous system diseases
• Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC Recruiting
  2023-504923-20-00 5 2024-04-04 Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer
• A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe … Recruiting
  2023-503412-33-00 5 2024-03-29 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cance
• A clinical study to compare MK-2870 with pembrolizumab to pembrolizumab alone in people with lung cancer (MK-2870-007) Recruiting
  2023-503376-24-00 5 2024-03-20 Metastatic non-small cell lung cancer (NSCLC)
• First in Human Study of TOS-358 in Adults with Soid Tumors Recruiting
  2023-505346-26-01 7 2024-02-19 9 main solid tumors – colorectal, cervical, endometrial, gastric, urot
• A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined … Recruiting
  2022-502113-28-00 5 2024-02-01 Follicular lymphoma
• A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N … Recruiting
  2022-502980-39-00 5 2024-01-25 Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
• PHASE II CLINICAL TRIAL TO ESTABLISH THE SAFETY OF THE USE OF EXPANDED ALLOGENEIC FETAL UMBILICAL CORD STEM MESENCHYMAL CELLS IN PRETERM PAT … Recruiting
  2024-516677-79-00 4 2024-01-11 Premature patients with bronchopulmonary dysplasia
• A trial to learn if odronextamab combined with lenalidomide is safe and works better than rituximab combined with lenalidomide in adult part … Recruiting
  2022-503092-28-00 5 2024-01-08 Relapsed/Refractory Follicular Lymphoma
• A study of STX-478 alone and in combination with other anticancer drugs in participants with advanced solid tumors. Recruiting
  2023-504807-94-00 7 2023-12-26 Breast Cancer; Advanced solid tumors including but not limited to gyne
• A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic B … Recruiting
  2022-503114-23-00 3 2023-12-19 Breast Cancer
• Safety, pharmacokinetics, and preliminary efficacy of VIR-5500 (AMX-500) in prostate cancer Recruiting
  2023-503495-24-00 1 2023-10-30 Hormone-refractory prostate cancer
• A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination with Checkpoint Inhibitor i … Recruiting
  2023-504709-35-00 1 2023-08-16 Locally advanced or metastatic solid tumors
• This study has 2 phases: a Phase 1b evaluation of elacestrant in combination with abemaciclib followed by a Phase 2 evaluation of elacestran … Recruiting
  2024-512878-98-00 9 2023-05-16 Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breas
• An adaptive, Phase 2, double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety, tolerability, immunogenicity, … Recruiting
  2022-500292-31-00 4 2023-05-12 Early stages of idiopathic Parkinson's Disease
• Clinical trial of androgen deprivation therapy combined with salvage radiotherapy when treating prostate cancer that has suffered recurrence … Recruiting
  2024-517666-41-00 5 2023-03-13 Prostate Cancer
• Phase I/Ib clinical trial of PM54 in Advance Solid Tumors patients Recruiting
  2023-508644-22-00 7 2023-02-28 Advance Solid Tumors
• A continued study in patients with Hematologic Cancers previously treated with Tafasitamab. Recruiting
  2022-500765-27-00 5 2022-11-03 Hematologic malignancies

Showing 121–144 of 344 trials